Form D · Biotechnology
Sonavex, Inc.
Baltimore, MD · CIK 0001645892
Offering snapshot reported Jul 28, 2026 · SEC filing
- Reported sold
- $3.1M Offering amount: $15M
- Investors reported
- 5 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jul 13, 2026 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jul 28, 2026 | Initial | $3,102,995 | No comparison | 5 | SEC filing |
| Nov 19, 2024 | Amendment | $15,000,004 | $12,700,004vs Feb 2, 2022 | 45 | SEC filing |
| Feb 2, 2022 | Initial | $2,300,000 | No comparison | 19 | SEC filing |
| Nov 1, 2019 | Initial | $1,800,000 | No comparison | 11 | SEC filing |
| Jan 19, 2017 | Amendment | $2,207,069 | $165,000vs Aug 18, 2016 | 12 | SEC filing |
| Aug 18, 2016 | Initial | $2,042,069 | No comparison | 10 | SEC filing |
| Oct 20, 2015 | Initial | $320,192 | No comparison | 6 | SEC filing |
| Jun 29, 2015 | Initial | $70,000 | No comparison | 2 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- Yes
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-592360
Source: Form D, filed Jul 28, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No matching detailed fund disclosure was found in the latest imported ADV filings. This does not establish that the issuer has no adviser.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Robert Hallenbeck | Director |
| Michael J. Hennessy, Jr. | Director |
| David Narrow | Director, Executive |
| Bill Niland | Director |
| William Niland | Director |
| Devin O'brien Coon | Director |
| Jerry Prince | Director |
| Evan Pritchard | Director |
| John Rappe | Executive |
| Alex Yevzlin | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
2835 O'donnell Street Suite 200
Baltimore, MD, 21224
Phone: 443.862.2024
Baltimore, MD, 21224
Phone: 443.862.2024